Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PTG 200

Next Previous
Drug Profile

PTG 200

Alternative Names: JNJ 67864238; JNJ-4238; PTG-200

Latest Information Update: 21 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protagonist Therapeutics
  • Developer Janssen Biotech; Protagonist Therapeutics
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Interleukin-23 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 31 Dec 2021 Discontinued - Phase-I for Crohn's disease (In volunteers) in Australia in Q4 2021 (PO)
  • 31 Dec 2021 Discontinued - Phase-II for Crohn's disease in USA, Argentina, Germany, Ukraine, Italy, Poland, Russia in Q4 2021 (PO)
  • 14 Dec 2021 Janssen Research & Development terminates the phase II PRISM trial in Crohn's disease in USA, Argentina, Germany, Ukraine, Italy, Poland, Russia(PO) as IAC futility criteria were met (NCT04102111)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top